Pazopanib in Treating Patients With Metastatic Urothelial Cancer

You may be eligible if

• Histologically or cytologically confirmed transitional cell cancer of the urothelium or bladder
• * Metastatic disease
• Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 2.0 cm by conventional techniques OR ≥ 1.0 cm by spiral CT scan
• No known brain metastases
• ECOG performance status 0-2
• Life expectancy ≥ 12 weeks
• Platelet count ≥ 100,000/mm\^3
• WBC ≥ 3,000/mm\^3
• Absolute neutrophil count ≥ 1,500/mm\^3
• Bilirubin normal
• AST and ALT ≤ 2.5 times upper limit of normal (ULN)
• Creatinine normal OR creatinine clearance ≥ 60 mL/min
• PT/INR/PTT ≤ 1.2 times ULN
• No proteinuria \> 1+ on two consecutive dipsticks measured ≥ 1 week apart
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No history of allergic reactions attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or other agents used in the study
• No condition that impairs the ability to swallow and retain pazopanib hydrochloride tablets, including any of the following:
• * Gastrointestinal tract disease resulting in an inability to take oral medication
• * Requirement for IV alimentation
• * Prior surgical procedures affecting absorption
• * Active peptic ulcer disease
• No uncontrolled illness that would limit compliance with study therapy including, but not limited to, any of the following:
• * Ongoing or active infection
• * Psychiatric illness or social situations
• No QTc prolongation (defined as a QTc interval ≥ 480 msecs) or other significant ECG abnormalities (e.g., frequent ventricular ectopy, evidence of ongoing myocardial ischemia)
• No other conditions, including any of the following:
• * Serious or non-healing wound, ulcer, or bone fracture
• * Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
• * Cerebrovascular accident within the past 6 months
• * Myocardial infarction, cardiac arrhythmia, or admission for unstable angina within the past 12 weeks
• * Venous thrombosis within the past 12 weeks
• * New York Heart Association (NYHA) class III or IV heart failure
• * Asymptomatic NYHA class II heart failure on treatment allowed
• No other active second malignancy other than non-melanoma skin cancer
• * Patients are not considered to have an active malignancy if they have completed anti-cancer therapy and are considered by their physician to be ≤ 30% risk of relapse
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) and recovered
• At least 4 weeks since prior radiotherapy
• Prior palliative radiotherapy to metastatic lesions allowed provided there is ≥ 1 measurable and/or evaluable lesion(s) that has not been irradiated
• At least 4 weeks since prior surgery
• One prior chemotherapy regimen for metastatic urothelial or bladder cancer
• More than 12 weeks since prior cardiac angioplasty or stenting
• Prior adjuvant or neoadjuvant therapy allowed
• No prior experimental treatment for metastatic disease
• No other prior or concurrent investigational agents
• No concurrent combination antiretroviral therapy for HIV-positive patients
• No concurrent CYP2C9 substrates, including any of the following:
• * Anticoagulants (e.g., warfarin \[therapeutic doses only\])
• * Low molecular weight heparin and prophylactic low-dose warfarin (≤ 2 mg daily) allowed
• * Oral hypoglycemics (e.g., glipizide, glyburide, tolbutamide, glimepiride, or nateglinide)
• * Ergot derivatives (e.g., dihydroergotamine, ergonovine, ergotamine, or methylergonovine)
• * Antipsychotics (e.g., pimozide or clozapine)
• * Erectile dysfunction agents (e.g., sildenafil, tadalafil, or vardenafil)
• * Antiarrhythmics (e.g., bepridil, flecainide, lidocaine, mexiletine, amiodarone, quinidine, or propafenone)
• * Immune modulators (e.g., cyclosporine, tacrolimus, or sirolimus)
• * Miscellaneous drugs (e.g., theophylline, quetiapine, risperidone, tacrine, or atomoxetine)
• No other concurrent anticancer agents or therapies
• No concurrent medications that are associated with a risk of QTc prolongation and/or Torsades de Pointes